Trocar Pharma Inc. develops small molecule therapeutics targeting diseases affecting the lung, kidney, gastrointestinal tract, and heart, utilizing a patented mechanism for precise intervention. Their therapeutics address conditions such as gastrointestinal acute radiation syndrome, chronic kidney disease, pulmonary fibrosis, and infectious diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for conditions like gastrointestinal acute radiation syndrome, pulmonary fibrosis, chronic kidney disease, and certain cancers have limitations in efficacy and can result in significant side effects. There is a need for therapeutics that can precisely target affected tissues and reverse cellular damage with minimal off-target effects.
Solution
Trocar Pharma is developing small molecule therapeutics designed to target and reverse cellular damage in diseases affecting the lung, kidney, gastrointestinal tract, and other organs. Their tissue-targeted platform technology focuses on modulating intercellular reactive oxygen species (ROS) and mitigating inflammation to promote tissue regeneration and increase survival. The company's lead compounds aim to address conditions such as gastrointestinal acute radiation syndrome (GI ARS) by increasing GI stem cell proliferation and reducing inflammation, as well as pulmonary fibrosis and chronic kidney disease by inhibiting fibrosis and ROS production. Trocar Pharma is also developing oncology medicines to treat breast, ovarian, and prostate cancers, including therapeutics for BRCA-1 mutated and Tamoxifen-resistant cancers.
Target Audience
The primary target audience includes patients suffering from gastrointestinal acute radiation syndrome, pulmonary fibrosis, chronic kidney disease, breast cancer, ovarian cancer, prostate cancer, and those at risk of severe COVID-19 complications.
Features
- Tissue-targeted platform technology for precise drug delivery
- Small molecule therapeutics designed to reverse cellular damage and counter apoptosis
- Compounds that modulate intercellular reactive oxygen species (ROS) and mitigate inflammation
- Lead compounds for GI ARS that increase GI stem cell proliferation and reduce inflammation
- Therapeutics for pulmonary fibrosis and chronic kidney disease that inhibit fibrosis and ROS production
- Oncology medicines for breast, ovarian, and prostate cancers, including BRCA-1 mimetics
- Potential COVID-19 therapeutics designed to mitigate the cytokine storm